Sutro Biopharma Inc (NASDAQ: STRO) kicked off on Monday, down -9.75% from the previous trading day, before settling in for the closing price of $1.59. Over the past 52 weeks, STRO has traded in a range of $1.50-$6.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 45.29% over the past five years. While this was happening, its average annual earnings per share was recorded -62.82%. With a float of $74.61 million, this company’s outstanding shares have now reached $82.40 million.
Let’s look at the performance matrix of the company that is accounted for 302 employees. In terms of profitability, gross margin is 59.3%, operating margin of -80.79%, and the pretax margin is -67.19%.
Sutro Biopharma Inc (STRO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sutro Biopharma Inc is 9.52%, while institutional ownership is 68.90%.
Sutro Biopharma Inc (STRO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -62.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.31% during the next five years compared to 21.96% growth over the previous five years of trading.
Sutro Biopharma Inc (NASDAQ: STRO) Trading Performance Indicators
Take a look at Sutro Biopharma Inc’s (STRO) current performance indicators. Last quarter, stock had a quick ratio of 3.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -3.04 in one year’s time.
Technical Analysis of Sutro Biopharma Inc (STRO)
Sutro Biopharma Inc (NASDAQ: STRO) saw its 5-day average volume 0.83 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 10.63%. Additionally, its Average True Range was 0.14.
During the past 100 days, Sutro Biopharma Inc’s (STRO) raw stochastic average was set at 0.16%, which indicates a significant decrease from 0.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.17% in the past 14 days, which was lower than the 81.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8614, while its 200-day Moving Average is $3.2072. Nevertheless, the first resistance level for the watch stands at $1.5600 in the near term. At $1.6850, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7500. If the price goes on to break the first support level at $1.3700, it is likely to go to the next support level at $1.3050. The third support level lies at $1.1800 if the price breaches the second support level.
Sutro Biopharma Inc (NASDAQ: STRO) Key Stats
The company with the Market Capitalisation of 118.33 million has total of 82,459K Shares Outstanding. Its annual sales at the moment are 153,730 K in contrast with the sum of -106,790 K annual income. Company’s last quarter sales were recorded 8,520 K and last quarter income was -48,790 K.
